CN105308066A - 类毒素、组合物和相关的方法 - Google Patents

类毒素、组合物和相关的方法 Download PDF

Info

Publication number
CN105308066A
CN105308066A CN201480021573.0A CN201480021573A CN105308066A CN 105308066 A CN105308066 A CN 105308066A CN 201480021573 A CN201480021573 A CN 201480021573A CN 105308066 A CN105308066 A CN 105308066A
Authority
CN
China
Prior art keywords
toxin
difficile
purified
toxoid
difficile toxin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480021573.0A
Other languages
English (en)
Chinese (zh)
Inventor
M.谢
M.索伊卡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Inc
Original Assignee
Sanofi Pasteur Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50489432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105308066(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Pasteur Inc filed Critical Sanofi Pasteur Inc
Publication of CN105308066A publication Critical patent/CN105308066A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Dermatology (AREA)
CN201480021573.0A 2013-03-15 2014-03-14 类毒素、组合物和相关的方法 Pending CN105308066A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361793376P 2013-03-15 2013-03-15
US61/793376 2013-03-15
PCT/US2014/029070 WO2014144594A1 (en) 2013-03-15 2014-03-14 Toxoid, compositions and related methods

Publications (1)

Publication Number Publication Date
CN105308066A true CN105308066A (zh) 2016-02-03

Family

ID=50489432

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480021573.0A Pending CN105308066A (zh) 2013-03-15 2014-03-14 类毒素、组合物和相关的方法

Country Status (13)

Country Link
US (1) US20160030542A1 (https=)
EP (1) EP2970400A1 (https=)
JP (1) JP2016519671A (https=)
KR (1) KR20150133771A (https=)
CN (1) CN105308066A (https=)
AR (1) AR095668A1 (https=)
AU (2) AU2014228983B2 (https=)
BR (1) BR112015023469A8 (https=)
CA (1) CA2907156A1 (https=)
HK (1) HK1213917A1 (https=)
SG (1) SG11201507578PA (https=)
TW (1) TW201518316A (https=)
WO (1) WO2014144594A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105611942A (zh) * 2013-06-14 2016-05-25 圣诺菲·帕斯图尔公司 针对艰难梭菌免疫的组合物和方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108003224A (zh) * 2017-12-20 2018-05-08 天康生物股份有限公司 一种多杀性巴氏杆菌毒素蛋白的纯化方法
US20250213667A1 (en) 2022-06-01 2025-07-03 Valneva Austria Gmbh Clostridium difficile vaccine
CN120615016A (zh) 2023-02-02 2025-09-09 葛兰素史克生物有限公司 免疫原性组合物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058353A1 (en) * 2003-12-16 2005-06-30 Acambis Inc. Passive immunization against clostridium difficile disease
CN101855336A (zh) * 2007-09-14 2010-10-06 赛诺菲巴斯德生物制剂公司 含艰难梭菌类毒素a和b的药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071759A (en) * 1986-05-30 1991-12-10 The United States Of America As Represented By The Secretary Of The Army Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B
MX2010001054A (es) 2007-07-26 2010-04-21 Sanofi Pasteur Ltd Composiciones adyuvantes antigenicas y metodos.
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005058353A1 (en) * 2003-12-16 2005-06-30 Acambis Inc. Passive immunization against clostridium difficile disease
CN101855336A (zh) * 2007-09-14 2010-10-06 赛诺菲巴斯德生物制剂公司 含艰难梭菌类毒素a和b的药物组合物

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JAMES MEADOR III: "Purification and Characterization of Toxin B from Clostridium difficile", 《INFECTION AND IMMUNITY》 *
N. M. SULLIVAN: "Purification and Characterization of Toxins A and B of Clostridium difficile", 《INFECTION AND IMMUNITY》 *
SARA W. ROTHMAN: "Differential Cytotoxic Effects of Toxins A and B Isolated from Clostridium difficile", 《INFECTION AND IMMUNITY》 *
傅思武: "艰难梭菌A毒素的纯化", 《中国生化药物杂志》 *
傅思武: "艰难梭菌B毒素的纯化及其生物学特性", 《中国生物制品学杂志》 *
王淼: "《食品生物化学》", 28 February 2009, 中国轻工业出版社 *
田亚平: "《生化分离技术》", 30 September 2006, 化学工业出版社 *
贾文祥: "《医学微生物学》", 31 August 2009, 四川大学出版社 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105611942A (zh) * 2013-06-14 2016-05-25 圣诺菲·帕斯图尔公司 针对艰难梭菌免疫的组合物和方法

Also Published As

Publication number Publication date
AR095668A1 (es) 2015-11-04
SG11201507578PA (en) 2015-10-29
CA2907156A1 (en) 2014-09-18
AU2018204879A1 (en) 2018-07-26
US20160030542A1 (en) 2016-02-04
KR20150133771A (ko) 2015-11-30
AU2014228983A1 (en) 2015-10-08
JP2016519671A (ja) 2016-07-07
TW201518316A (zh) 2015-05-16
WO2014144594A1 (en) 2014-09-18
AU2014228983B2 (en) 2018-04-05
WO2014144594A8 (en) 2014-11-13
EP2970400A1 (en) 2016-01-20
BR112015023469A2 (pt) 2017-07-18
HK1213917A1 (zh) 2016-07-15
BR112015023469A8 (pt) 2019-12-03

Similar Documents

Publication Publication Date Title
TWI624474B (zh) 類毒素、組合物及相關方法
AU2018204879A1 (en) Toxoid, compositions and related methods
CN104487086A (zh) 无动物源的不含酒精的疫苗组合物及其制备方法
US20090060904A1 (en) Vegetarian Protein A Preparation and Methods Thereof
JP2016519671A5 (https=)
JPH03191789A (ja) 百日咳菌からの６９０００ダルトンの抗原性タンパク質の精製方法
US7201912B2 (en) Recombinant immunogenic compositions and methods for protecting against lethal infections from Bacillus anthracis
EP3901163B1 (en) Botulinum toxin producing method
NZ566871A (en) Protein A Production and Purification without Using Animal Derived Components involving staphylococcus aureus
JP3629555B2 (ja) ボルデテラからの細胞結合蛋白質の抽出
WO2009016651A1 (en) Simplified means for obtaining prn from bordetella pertussis
CN113980103B (zh) 一种mSEB抗原蛋白的纯化方法
RU2407792C1 (ru) СПОСОБ ПОЛУЧЕНИЯ IgAl-ПРОТЕАЗЫ ИЗ КУЛЬТУРЫ NEISSERIA MENINGITIDIS СЕРОГРУППЫ А И ИММУНОГЕННЫЙ ПРЕПАРАТ НА ЕЕ ОСНОВЕ
JPS60248623A (ja) 緑膿菌感染に対してワクチン活性を有するリポ糖蛋白ｐｓｃ―ａおよび緑膿菌ワクチン
HK1210210A1 (en) Purification of virus like particles

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20160203

WD01 Invention patent application deemed withdrawn after publication